Q-omics provides the consensus-scored HUS1B profile across patient tissues and cancer cell-line models. HUS1B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HUS1B is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, HUS1B RNA expression shows 12,506 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KICH, and ACC as cancer lineages where HUS1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HUS1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HUS1B survival associations across molecular data types. HUS1B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HUS1B RNA expression–survival associations across cancer types. High HUS1B expression shows unfavorable associations in KIRC, ACC and MESO, but favorable associations in BRCA, SCLC and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HUS1B RNA expression.
This table summarizes HUS1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for HUS1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HUS1B shows lower tumor expression in KICH and higher tumor expression in HNSC, COAD, LIHC, LUSC and STAD. The KICH box plot shows higher HUS1B RNA expression in normal versus tumor tissue (log2 FC = −0.404, t-test p < 0.001).
This table shows molecular features associated with HUS1B in patient tissues and cancer cell lines. In patient samples, HUS1B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HUS1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SKIN.
